Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin Supplementation in Septic Patients
NCT03950778Phase 1Completed
- Sponsor
- University of Pécs
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of albumin (human) in sepsis and septic shock (2 arms), sponsored by University of Pécs. Primary endpoint: C-Reactive Protein Concentration at Day 5. Started Mar 2023; status: completed.
02
Drugs
albumin (human)
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT03950778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950778.